What's Happening?
Conexeu Sciences Inc., a preclinical-stage medical device company, has announced the early-stage development of two new fabricated formats for its investigational CXU™ platform: W.A.F.E.R.™ Sheet and W.A.F.E.R.™ Lattice. These new formats are designed
to expand the application of their collagen-based scaffold platform for wound management, addressing a wider range of wound geometries and handling needs. The W.A.F.E.R.™ Sheet is conceived as a flexible, dry sheet for broad wound surfaces, while the W.A.F.E.R.™ Lattice is a lyophilized, three-dimensional scaffold intended for large volumetric defects, designed to be shaped by clinicians at the point of care. These additions complement Conexeu's existing flowable CXU™ device candidate, which is applied by syringe and forms a stable 3D scaffold in situ. The company's Chief Scientific Officer, Dr. Claudia Chavez-Munoz, stated that the immediate focus is on reproducible fabrication and characterization of these new formats, followed by preclinical evaluation. Conexeu continues to target a planned FDA 510(k) submission for its flowable lead device candidate in the first calendar quarter of 2027.
Why It's Important?
The development of W.A.F.E.R.™ Sheet and W.A.F.E.R.™ Lattice by Conexeu Sciences is significant for the advanced wound care market. Current wound care often faces challenges due to the diverse nature of wounds, which vary greatly in depth, geometry, and accessibility. By offering multiple formats—flowable, sheet, and lattice—Conexeu aims to provide clinicians with more versatile tools to manage a broader spectrum of wound types, from shallow surfaces to complex, deep volumetric defects. This modular approach could lead to more effective and tailored treatments, potentially improving patient outcomes and reducing healing times. The ability to shape the lattice format at the point of care could also streamline surgical procedures and enhance adaptability in clinical settings. If successful, these innovations could position Conexeu as a key player in the regenerative medicine space, offering comprehensive solutions for tissue restoration and potentially expanding into broader reconstructive applications beyond initial wound management.
What's Next?
Conexeu Sciences will proceed with the fabrication and characterization of the W.A.F.E.R.™ Sheet and W.A.F.E.R.™ Lattice formats, followed by preclinical evaluation. These new formats are in early-stage development and will follow their own regulatory pathways, separate from the company's lead flowable CXU™ device candidate. The company's near-term focus remains on its planned FDA 510(k) submission for the flowable device candidate in the first calendar quarter of 2027, contingent on successful completion of required testing, manufacturing activities, and regulatory documentation. Following potential FDA clearance, wound care is expected to be Conexeu's first commercial indication. Future investigations may explore the modular nature of these formats for broader reconstructive applications. The company will need to secure additional funding and conduct further research to bring these new formats through the regulatory process and eventually to market.
Beyond the Headlines
The expansion of the CXU™ platform with W.A.F.E.R.™ Sheet and W.A.F.E.R.™ Lattice highlights a broader trend in medical device innovation towards personalized and adaptable solutions. The ability to tailor scaffold formats to specific wound geometries reflects a growing understanding of the complexities of tissue regeneration and the need for materials that can conform to diverse biological environments. This approach could reduce complications associated with ill-fitting wound dressings and scaffolds, potentially leading to more predictable healing processes. Furthermore, the use of collagen-based scaffolds aligns with the increasing demand for biocompatible and bioresorbable materials in regenerative medicine, aiming to integrate seamlessly with the body's natural healing mechanisms. The long-term implications could include a shift towards more sophisticated, multi-format platforms for tissue engineering, impacting not only wound care but also other reconstructive and regenerative surgical fields.













